Evidence map›Paper›PMID 39771639›Full record

ReviewSensors (Basel, Switzerland)2024

Emerging Sensing Technologies for Liquid Biopsy Applications: Steps Closer to Personalized Medicine.

Panagiota M Kalligosfyri, Eleni Lamprou, Despina P Kalogianni

Abstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Panagiota M KalligosfyriDepartment of Chemistry, University of Patras, GR26504 Patras, Greece.ORCID 0000-0002-8287-059X
Eleni LamprouDepartment of Chemistry, University of Patras, GR26504 Patras, Greece.ORCID 0000-0002-5179-3018
Despina P KalogianniDepartment of Chemistry, University of Patras, GR26504 Patras, Greece.ORCID 0000-0001-9638-8713

Funding

Hellenic Foundation for Research and Innovation 9098
6 · The paper itself

Abstract

Liquid biopsy is an efficient diagnostic/prognostic tool for tumor-derived component detection in peripheral circulation and other body fluids. The rapid assessment of liquid biopsy techniques facilitates early cancer diagnosis and prognosis. Early and precise detection of tumor biomarkers provides crucial information about the tumor that guides clinicians towards effective personalized medicine. Point-of-care-testing remains still a great challenge in cancer diagnostics. Liquid biopsy is a promising alternative to tissue biopsy with the great advantages of less invasion and real-time monitoring of the disease, also providing information about tumor heterogeneity. The field is continuously and rapidly expanding. Numerous sophisticated biosensors have been developed targeting several biomarkers to achieve low detection limits, increased specificity and robustness. Current biosensors include mainly optical sensors, such as colorimetric, fluorescent, SPR, SERS and lateral flow assays. Electrochemical sensors have also been developed, providing very low detection limits. Colorimetric sensors exhibited simplicity in signal interpretation, while fluorescent sensors contributed to low analysis times, and SPR/SERS enabled label-free and rapid analysis. Novel target amplification and signal enhancement techniques have been exploited to increase the detectability of the sensors. In this context, this review is focused on the recent advances in biosensing technology for cutting-edge liquid biopsy applications towards point-of-care testing.

Indexed as

Biomarkers, TumorBiosensing TechniquesPrecision MedicineColorimetryHumansLiquid BiopsyNeoplasmsBiomarkers, Tumorcirculating tumor cellscirculating tumor DNAcolorimetric sensorsexosomesfluorescent sensorslateral flow assaymicroRNAoptical sensorsSERSSPR

Identifiers

PMID39771639
PMCPMC11678935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.